TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06342583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced social relations training with technical device
Description: 15 participants from the experimental group will undergo a first part in which they will be guided through social stories to construct an appropriate conversation repertoire. In the first phase the participants will see 8 social stories with scenes from everyday life and after learning the correct mode of interaction and communication they will be asked to interact in the group by playing the roles previously seen in the social stories. These will be shown on a technological device. Participants will have the opportunity to choose the correct mode of interaction by selecting it directly on the technological device. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media. Slides will be shown to explain risks and correct use and the operator will show on the technological device (Smartphone) all the practical steps to be taken (e.g. privacy settings).

Intervention type: OTHER
Group type: OTHER
Intervention: Advanced social relations training without technical device
Description: 15 participants from the control group will undergo a first part in which they will be guided through social stories to build an appropriate conversation repertoire. In the first phase, the participants will see eight social stories illustrating scenes from everyday life and, after learning the correct modes of interaction and communication, they will be invited to interact in the group by playing the roles previously seen in the social stories. These will be shown in traditional mode (flashcards). Participants will have the opportunity to choose the correct mode of interaction by touching the card showing the appropriate mode. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media (facebook, instagram, TikTok, Whatsapp, YouTube). The trainer will show images on paper related to risks and correct use of social media.
Study: NCT05666921

Intervention type: OTHER
Intervention: psychological assessment
Description: The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.

Intervention type: OTHER
Intervention: psychological assessment
Description: The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
Study: NCT05815485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: 30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: 30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
Study: NCT05602129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK36273
Description: HSK36273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK36273
Description: HSK36273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium
Description: Heparin sodium
Study: NCT05220748

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RM-1995
Description: RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RM-1995
Description: RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
Study: NCT06013202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil Mouth Rinse
Description: Nigella Sativa Oil Mouth Rinse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
Description: isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
Study: NCT06055023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 12.5mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 25mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 50mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 100mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 200mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 300mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 450mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82 600mg
Description: 1 case,The starting dose,Take the medicine once on D1,D1-7.
Study: NCT05390463

Intervention type: OTHER
Intervention: PERformance guided Fracture Rehablitation Method (PERFoRM) protocol.
Description: A structured rehabilitation protocol for surgically treated peri-articular fractures of the upper extremity (proximal humerus and distal radius fractures).
Study: NCT06385522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BITR2101
Description: TNFR2 monoclonal antibody
Study: NCT06510387

Intervention type: DEVICE
Intervention: Ultrasound using suprasternal method
Description: The research resident will perform suprasternal ultrasound (US) with a curvilinear probe) C6-2) of US machine (Philips Affiniti 50) which will be placed transversely on the suprasternal area just above to the suprasternal notch immediately after intubation, The position of the trachea will be determined by a hyperechoic air-mucosa (A-M) interface with reverberation artifact posteriorly (comet-tail artifact).~The position of endotracheal tube (ETT), when it is placed in trachea, will be defined as observable contour between A-M and comet-tail artifact. If the second contour appears, it will be similar to the second airway which is called double-tract sign which means that the ETT will be in the esophagus. (7) If the position of the esophagus is suspected of being exactly behind the trachea, operator of ultrasound can specify the location of the esophagus by moving the probe to the left and right sides during scan.

Intervention type: DEVICE
Intervention: Ultrasound using suprasternal method
Description: The research resident will perform suprasternal ultrasound (US) with a curvilinear probe) C6-2) of US machine (Philips Affiniti 50) which will be placed transversely on the suprasternal area just above to the suprasternal notch immediately after intubation, The position of the trachea will be determined by a hyperechoic air-mucosa (A-M) interface with reverberation artifact posteriorly (comet-tail artifact).~The position of endotracheal tube (ETT), when it is placed in trachea, will be defined as observable contour between A-M and comet-tail artifact. If the second contour appears, it will be similar to the second airway which is called double-tract sign which means that the ETT will be in the esophagus. (7) If the position of the esophagus is suspected of being exactly behind the trachea, operator of ultrasound can specify the location of the esophagus by moving the probe to the left and right sides during scan.

Intervention type: DEVICE
Intervention: Ultrasound using subxiphoid method
Description: Immediately after suprasternal sonography, the research resident will perform subxiphoid sonography to detect diaphragmatic motion, and information will be recorded.

Intervention type: DEVICE
Intervention: Ultrasound using subxiphoid method
Description: Immediately after suprasternal sonography, the research resident will perform subxiphoid sonography to detect diaphragmatic motion, and information will be recorded.
Study: NCT06061211

Intervention type: OTHER
Group type: OTHER
Intervention: TREADMILL(SIDEA-Germany treadmill ) with TENS
Description: TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: SIDEA-Germany treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TREADMILL(SIDEA-Germany treadmill ) with TENS
Description: TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: SIDEA-Germany treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min.
Study: NCT04512365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A capsule that contains only dextrose filler administered during the first or second laboratory visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
Study: NCT04327661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT05153668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus Oral Tablet
Description: Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
Study: NCT05585125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol
Study: NCT05639010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: regular hemodialysis
Description: Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regular hemodialysis
Description: Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion combined with hemodialysis
Description: Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
Study: NCT04614103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
Study: NCT05837728

Intervention type: BEHAVIORAL
Intervention: Health promoting assessment of older adults living at home
Description: Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
Study: NCT05065736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Clofarabine
Description: The participants enrolled will receive a baseline CFA PET/CT evaluation. Then, the participants will undergo the routine follow up would normally occur for their cancer and its treatment. If this routine follow up and care involves repeat imaging of the cancer, then the CFA PET/CT scan will be repeated at that time (timed according to standard-of-care follow-up imaging), which is expected between a month to about 4 months after the first CFA PET/CT scan. The study period will end 24 hours after this repeat PET/CT scan.
Study: NCT04895995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daylight dCBT Application
Description: Participants will complete up to four modules of digital intervention delivered in a self-paced format.
Study: NCT05094544

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-ablative SBRT
Description: Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
Study: NCT04717388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acoustics tests, Questionaries,
Description: acoustics tests at V1 Questionaries at V1~* cognitive~* emotional~* auditory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acoustics tests, Questionaries,
Description: acoustics tests at V1 Questionaries at V1~* cognitive~* emotional~* auditory

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: Anatomical and functional MRI at V2
Study: NCT06030830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMaRT Mom
Description: SMaRT Mom intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention.
Study: NCT05958654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool
Description: DETECT is an elder mistreatment (EM) screening tool created for medics in the Fort Worth Texas area to use when responding to the homes of older adults, enabling them to screen for signs of elder mistreatment. DETECT-RPC is the adapted version of this tool designed specifically for use by home-based primary care (HBPC) clinicians.~The DETECT-RPC tool is designed to:~1. Be brief and easy to use.~2. Focus on the clinician's direct observations of the older adult and their physical and social environment.~3. Provide clear guidance on reporting suspected EM.~4. Integrate seamlessly into existing procedures and medical charting systems.
Study: NCT05956353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling Intervention
Description: Culturally tailored narrative-based videos created by individuals to promote colorectal, breast and cervical cancer screening among eligible participants in a primary care practice.
Study: NCT05481918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based therapy after ACL reconstruction
Description: Five physiotherapeutic supervisions (individual) take place within the first 12-13 weeks after ACL reconstruction with focus on home exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized ambulant therapy after ACL reconstruction
Description: 16 physiotherapeutic supervisions (groups+ individual) take place within the first 12-13 weeks after ACL reconstruction.
Study: NCT06480578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISS-SBDOH arm
Description: Once the ID-Cap ISS system has identified a participant who has missed his/her prescribed ARVs for five (5) consecutive days, a member of the multidisciplinary team will be informed automatically by the system and reach out to the participant immediately. The team will work with the primary provider and the participant to evaluate and understand the patient's SBDOH profile and status and develop a coordinated plan that fits the patient's specific need to address the patient's particular challenges in SBDOH. This plan (all SBDOH interventions) is considered standard of care and would be initiated in the same manner regardless of participation. Participation in this study will not alter the planned interventions determined by the HIV Care team.
Study: NCT06233474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state

Intervention type: DRUG
Group type: OTHER
Intervention: Allocetra
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.
Study: NCT05530382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-guided learning
Description: video-based self-directed learning for medical device training
Study: NCT04932746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
Study: NCT05566353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Check
Description: Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,